The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 20, 2020

Filed:

May. 16, 2018
Applicant:

University of Tennessee Research Foundation, Knoxville, TN (US);

Inventors:

Ramesh Narayanan, Cordova, TN (US);

Duane D. Miller, Collierville, TN (US);

Thamarai Ponnusamy, Memphis, TN (US);

Dong-Jin Hwang, Arlington, TN (US);

Yali He, Germantown, TN (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4164 (2006.01); A61K 31/40 (2006.01); A61K 31/415 (2006.01); A61K 31/5375 (2006.01); A61K 31/4196 (2006.01); A61K 31/41 (2006.01); A61K 31/44 (2006.01); A61K 31/517 (2006.01); A61K 31/277 (2006.01); A61K 31/655 (2006.01); A61K 31/4192 (2006.01); A61K 31/4439 (2006.01); C07D 209/08 (2006.01); C07D 213/75 (2006.01); C07D 231/18 (2006.01); C07D 231/40 (2006.01); C07D 233/56 (2006.01); C07D 303/48 (2006.01); C07D 249/06 (2006.01); C07D 231/12 (2006.01); C07D 207/32 (2006.01); C07D 231/38 (2006.01); C07D 249/14 (2006.01); C07D 207/33 (2006.01); C07D 257/04 (2006.01); C07D 213/84 (2006.01); C07D 231/16 (2006.01); C07D 233/68 (2006.01); C07D 401/12 (2006.01); C07D 239/74 (2006.01); C07D 249/08 (2006.01); C07D 207/06 (2006.01); C07D 207/34 (2006.01); C07D 295/15 (2006.01); A61P 35/00 (2006.01); C07C 317/46 (2006.01); C07C 255/60 (2006.01); C07D 249/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4164 (2013.01); A61K 31/277 (2013.01); A61K 31/40 (2013.01); A61K 31/41 (2013.01); A61K 31/415 (2013.01); A61K 31/4192 (2013.01); A61K 31/4196 (2013.01); A61K 31/44 (2013.01); A61K 31/4439 (2013.01); A61K 31/517 (2013.01); A61K 31/5375 (2013.01); A61K 31/655 (2013.01); A61P 35/00 (2018.01); C07C 255/60 (2013.01); C07C 317/46 (2013.01); C07D 207/06 (2013.01); C07D 207/32 (2013.01); C07D 207/33 (2013.01); C07D 207/34 (2013.01); C07D 209/08 (2013.01); C07D 213/75 (2013.01); C07D 213/84 (2013.01); C07D 231/12 (2013.01); C07D 231/16 (2013.01); C07D 231/18 (2013.01); C07D 231/38 (2013.01); C07D 231/40 (2013.01); C07D 233/56 (2013.01); C07D 233/68 (2013.01); C07D 239/74 (2013.01); C07D 249/04 (2013.01); C07D 249/06 (2013.01); C07D 249/08 (2013.01); C07D 249/14 (2013.01); C07D 257/04 (2013.01); C07D 295/15 (2013.01); C07D 303/48 (2013.01); C07D 401/12 (2013.01);
Abstract

This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.


Find Patent Forward Citations

Loading…